Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intellia Therapeutics Inc NTLA

Healthcare Biotechnology
Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its... see more

Recent & Breaking News (NDAQ:NTLA)

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

GlobeNewswire March 10, 2021

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results

GlobeNewswire February 25, 2021

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates

GlobeNewswire February 18, 2021

Intellia Therapeutics Highlights Strategic Priorities and Anticipated Development Milestones for 2021

GlobeNewswire January 7, 2021

Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

GlobeNewswire December 12, 2020

Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting

GlobeNewswire December 5, 2020

Intellia Therapeutics Announces Closing of $201 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire December 4, 2020

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire December 1, 2020

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

GlobeNewswire November 30, 2020

Intellia Therapeutics Receives Grant to Develop Curative CRISPR/Cas9 In Vivo Sickle Cell Disease Treatments

GlobeNewswire November 11, 2020

Intellia Therapeutics Doses First Patient in Landmark CRISPR/Cas9 Clinical Trial of NTLA-2001 for the Treatment of Transthyretin Amyloidosis

GlobeNewswire November 9, 2020

Intellia Therapeutics Announces Third Quarter 2020 Financial Results

GlobeNewswire November 5, 2020

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2020 Earnings and Company Updates

GlobeNewswire October 29, 2020

Intellia Therapeutics Receives Authorization to Initiate Phase 1 Clinical Trial of NTLA-2001 for Transthyretin Amyloidosis (ATTR)

GlobeNewswire October 19, 2020

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology

GlobeNewswire October 7, 2020

Intellia Therapeutics Names John F. Crowley to Board of Directors

GlobeNewswire October 5, 2020

Intellia Therapeutics Presents New Preclinical Data Showing Persistent In Vivo Editing and Durability of Effect Following CRISPR/Cas9-Based Treatment

GlobeNewswire September 29, 2020

Intellia Therapeutics to Present at Chardan's Virtual 4th Annual Genetic Medicines Conference

GlobeNewswire September 28, 2020

Intellia Therapeutics to Present at Baird's 2020 Virtual Global Healthcare Conference

GlobeNewswire September 2, 2020

Intellia Therapeutics Announces Second Quarter 2020 Financial Results

GlobeNewswire August 6, 2020